Cancer Survival and Excess Mortality Estimates among Adolescents and Young Adults in Western Australia, 1982-2004: A Population-Based Study

Background: Data are limited on cancer outcomes in adolescents and young adults. Methods: Based on data from the Western Australian Data Linkage System, this study modelled survival and excess mortality in all adolescents and young adults aged 15-39 years in Western Australia who had a diagnosis of cancer in the period 1982-2004. Relative survival and excess all-cause mortality for all cancers combined and for principal tumour subgroups were estimated, using the Ederer II method and generalised linear Poisson modelling, respectively. Results: A cancer diagnosis in adolescents and young adults conferred substantial survival decrement. However, overall outcomes improved over calendar period (excess mortality hazard ratio [HR], latest versus earliest diagnostic period: 0.52, trend <0.0001). Case fatality varied according to age group (HR, oldest versus youngest: 1.38, trend <0.0001), sex (HR, female versus male: 0.66, 95% confidence interval [CI] 0.62-0.71), ethnicity (HR, Aboriginal versus others: 1.47, CI 1.23-1.76), geographical area (HR, rural/remote versus urban: 1.13, CI 1.04-1.23) and residential socioeconomic status (HR, lowest versus highest quartile: 1.14, trend <0.05). Tumour subgroups differed substantially in frequency according to age group and sex, and were critical outcome determinants. Conclusions: Marked progressive calendar-time improvement in overall outcomes was evident. Further research is required to disentangle the contributions of tumour biology and health service factors to outcome disparities between ethno-demographic, geographic and socioeconomic subgroups of adolescents and young adults with cancer. © 2013 Haggar et al

Cancer incidence and mortality trends in Australian adolescents and young adults, 1982-2007

Background: Increasing incidence and lack of survival improvement in adolescents and young adults (AYAs) with cancer have led to increased awareness of the cancer burden in this population. The objective of this study was to describe overall and type-specific cancer incidence and mortality trends among AYAs in Western Australia from 1982-2007.Methods: Age-adjusted incidence and mortality rates were calculated for all malignancies combined and for each of the most common diagnostic groups, using five-year age-specific rates. Joinpoint regression analysis was used to derive annual percentage changes (APC) for incidence and mortality rates.Results: The annual incidence rate for all cancers combined increased in males from 1982 until 2000 (APC = 1.5%, 95%CI: 0.9%; 2.1%) and then plateaued, whilst rates for females remained stable across the study period (APC = -0.1%; 95%CI: -0.2%; 0.4%) across the study period. For males, significant incidence rate increases were observed for germ cell tumors, lymphoblastic leukemia and thyroid cancer. In females, the incidence of Hodgkin's lymphoma, colorectal and breast cancers increased. Significant incidence rate reductions were noted for cervical, central nervous system and lung cancers. Mortality rates for all cancers combined decreased from 1982 to 2005 for both males (APC = -2.6%, 95%CI:-3.3%;-2.0%) and females (APC = -4.6%, 95%CI:-5.1%;-4.1%). With the exception of bone sarcoma and lung cancer in females, mortality rates for specific cancer types decreased significantly for both sexes during the study period.Conclusions: Incidence of certain AYA cancers increased, whilst it decreased for others. Mortality rates decreased for most cancers, with the largest improvement observed for breast carcinomas. Further research is needed to identify the reasons for the increasing incidence of certain cancers. © 2012 Haggar et al.; licensee BioMed Central Ltd

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication

Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk Factors

In this article, the incidence, mortality, and survival rates for colorectal cancer are reviewed, with attention paid to regional variations and changes over time. A concise overview of known risk factors associated with colorectal cancer is provided, including familial and hereditary factors, as well as environmental lifestyle-related risk factors such as physical inactivity, obesity, smoking, and alcohol consumption

Selected adverse obstetric and perinatal outcomes according to AYA cancer characteristics and treatment details, Adjusted Relative Risk versus non-cancer comparison group (95% CI)^a.

a<p>The final models were adjusted for: Aboriginal status, previous cesarean section, maternal smoking, use of fertility treatment, residential remoteness, hospital status.</p><p>Selected adverse obstetric and perinatal outcomes according to AYA cancer characteristics and treatment details, Adjusted Relative Risk versus non-cancer comparison group (95% CI)^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0113292#nt101" target="_blank">a</a>}.</p

Diagnostic characteristics and treatment details of AYAs diagnosis, Western Australia, 1982–2007.

<p>Diagnostic characteristics and treatment details of AYAs diagnosis, Western Australia, 1982–2007.</p

Risk of adverse maternal and infant outcomes after assisted vaginal delivery compared with unassisted vaginal for 158,241^a WA vaginal births.

a<p>Restricted to vaginal, singleton, term births (37–41 completed weeks), where the infant was live born and without birth defects.</p>b<p>Adjusted for year of birth, maternal age, parity, patient status (not in stratified analysis), hospital type (private/public/tertiary), smoking during pregnancy, marital status, ethnicity (Caucasian/Indigenous/other), pre-existing medical conditions (asthma/hypertension/diabestes), SES quintiles, residential remoteness, gestation, infant weight, pregnancy complications, labour and delivery complications, analgesia during labour (none/gas or intramuscular/epidural/spinal), and whether the labour was induced.</p>c<p>Apgar score at 5 minutes = 0–6.</p>d<p>Endotracheal intubation or external cardiac massage.</p

Risk of adverse infant outcomes for assisted vaginal deliveries compared with unassisted deliveries in 158,241 WA public and private patient birth admissions.

<p>X-axis represents odds ratios (middle black dots) and 95% confidence intervals (top and bottom black dots). Logistic regression models -adjusted for the same factors as in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0061699#pone-0061699-t003" target="_blank">Table 3</a>- were run separately for private and public patients to calculate separate odds ratios (ORs) for the risk of adverse infant outcomes for assisted vaginal deliveries compared with unassisted deliveries.</p

5- and 10-year relative survival ratio for the most recent diagnosis period, 2000–2004.^a

a<p>Bone Sarcoma not included among subgroup analyses; CI: confidence intervals.</p

Distribution of each diagnostic groups and selected carcinomas displayed by age group.

<p>Distribution of each diagnostic groups and selected carcinomas displayed by age group.</p